1. Bar-Oh A, et al. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs 2014;74:74659–74.
2. Cherwinski HM, et al. The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism. J Pharmacol Exp Ther 1995;272:460-8.
3. Confavreux C, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014;13:247–56.
4. Coyle PK, et al. Patient-reported outcomes in relapsing forms of MS: Real-world, global treatment experience with teriflunomide from the Teri-PRO study. Mult Scler Relat Disord 2017;17:107–15.
5. Freedman MS, et al. The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies. Mult Scler J 2018;24(Suppl 2):530–737; P1233.
6. Hauser SL, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med 2020;383:546–57.
7. Kappos L, et al. Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial. JAMA Neurol 2021;78:558–67.
8. Miller AE, et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. J Neurol 2014;261(Suppl 1): 1781–8.
9. O’Connor P, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365:1293–303.
10. Oh J, et al. Imaging outcome measures of neuroprotection and repair in MS: a consensus statement from NAIMS. Neurology 2019;92(Suppl):P2–047.
11. Radue EW, et al. Teriflunomide slows BVL in relapsing MS: a reanalysis of the TEMSO MRI data set using SIENA. Neurol Neuroimmunol Neuroinflamm 2017;4:e390.